Shoring Up Osteoporosis Management: A Fresh Start?
Noah Furr1, Ansley Ulmer1, Brock Cardon2
1From the Nellis Family Medicine Residency, Nellis AFB, Las Vegas, NV.
Anabolic bone agents, including parathyroid hormone receptor agonists and sclerostin inhibitors, show greater effectiveness in preventing fractures in women with osteoporosis compared to bisphosphonates.
Area of Science:
- Bone biology and pharmacology
- Osteoporosis treatment strategies
- Clinical fracture prevention
Background:
- Bisphosphonates are a common treatment for osteoporosis.
- Severe osteoporosis poses a significant fracture risk.
- Need for superior fracture prevention agents is critical.
Purpose of the Study:
- To compare the efficacy of anabolic bone agents versus bisphosphonates.
- To evaluate fracture prevention in women with varying osteoporosis severity.
- To assess specific anabolic agents: parathyroid hormone receptor agonists and sclerostin inhibitors.
Main Methods:
- Comparative analysis of anabolic agents (teriparatide, abaloparatide, romosozumab) and bisphosphonates.
- Focus on prevention of clinically significant and vertebral fractures.
- Study population includes women with and without severe osteoporosis.
Main Results:
- Anabolic bone agents demonstrated superior fracture prevention.
- Effectiveness observed in both severe and non-severe osteoporosis cases.
- Specific agents like teriparatide, abaloparatide, and romosozumab outperformed bisphosphonates.
Conclusions:
- Anabolic bone agents represent a more effective therapeutic option for fracture prevention in osteoporosis.
- These agents offer improved outcomes over bisphosphonates, particularly in high-risk populations.
- Further research may explore optimal sequencing and combination therapies.
More Related Videos
07:12Semiautomated Longitudinal Microcomputed Tomography-based Quantitative Structural Analysis of a Nude Rat Osteoporosis-related Vertebral Fracture Model
Published on: September 28, 2017
03:56Author Spotlight: Exploring the Impact of Lingnan Fire-Needle Therapy in Osteoporosis Intervention
Published on: April 26, 2024
Related Concept Videos
Osteoclasts in Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone Remodeling
Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
